D. Boral Capital Reiterates Buy Rating for Clene (NASDAQ:CLNN)

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating reiterated by D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $23.00 price objective on the stock. D. Boral Capital’s target price would suggest a potential upside of 443.74% from the stock’s previous close.

CLNN has been the topic of several other reports. Canaccord Genuity Group cut their price objective on shares of Clene from $86.00 to $83.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Benchmark cut their price target on shares of Clene from $90.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Clene in a report on Thursday, November 14th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Clene currently has an average rating of “Buy” and a consensus target price of $55.25.

Clene Stock Down 4.5 %

Shares of NASDAQ:CLNN opened at $4.23 on Tuesday. The company has a market cap of $35.24 million, a P/E ratio of -0.80 and a beta of 0.24. The business has a fifty day simple moving average of $4.81 and a 200-day simple moving average of $5.06. Clene has a 52 week low of $3.82 and a 52 week high of $10.40.

Institutional Trading of Clene

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in Clene during the fourth quarter worth approximately $69,000. Fullcircle Wealth LLC acquired a new position in shares of Clene during the 4th quarter valued at $69,000. Renaissance Technologies LLC purchased a new stake in Clene during the 4th quarter worth $96,000. Parsons Capital Management Inc. RI acquired a new stake in Clene in the 4th quarter valued at $194,000. Finally, Geode Capital Management LLC raised its position in Clene by 52.9% in the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after purchasing an additional 22,539 shares during the period. Institutional investors and hedge funds own 23.28% of the company’s stock.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.